Q1 EPS Estimate for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Zacks Research lowered their Q1 2027 earnings per share estimates for shares of Axsome Therapeutics in a report issued on Friday, December 26th. Zacks Research analyst Team now expects that the company will earn $0.59 per share for the quarter, down from their previous forecast of $0.69. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Several other brokerages also recently weighed in on AXSM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Guggenheim increased their price objective on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Needham & Company LLC reissued a “buy” rating and set a $154.00 target price on shares of Axsome Therapeutics in a report on Tuesday, November 4th. Morgan Stanley upped their price target on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Wells Fargo & Company reduced their price objective on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating for the company in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $179.88.

Axsome Therapeutics Trading Down 1.3%

Shares of NASDAQ:AXSM opened at $148.79 on Monday. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a 52-week low of $79.19 and a 52-week high of $158.56. The stock has a market cap of $7.50 billion, a price-to-earnings ratio of -31.86 and a beta of 0.47. The business has a 50-day moving average price of $144.13 and a 200-day moving average price of $124.10.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm’s quarterly revenue was up 63.2% on a year-over-year basis.

Insider Activity

In other news, CEO Herriot Tabuteau sold 10,558 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,071,193.22. This trade represents a 59.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 289,296 shares of company stock worth $38,882,311. Corporate insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently bought and sold shares of the business. Allworth Financial LP grew its holdings in Axsome Therapeutics by 6.6% in the third quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after purchasing an additional 89 shares during the period. CIBC Private Wealth Group LLC lifted its position in shares of Axsome Therapeutics by 5.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 14,375 shares of the company’s stock valued at $1,746,000 after buying an additional 686 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Axsome Therapeutics in the 3rd quarter valued at $524,000. Wilmington Savings Fund Society FSB increased its holdings in Axsome Therapeutics by 4,375.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 716 shares of the company’s stock worth $87,000 after acquiring an additional 700 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new position in Axsome Therapeutics during the third quarter worth $40,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.